Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...

Less than a year after garnering the first anti-CLDN18.2 approval in the U.S., Astellas Pharma is not resting on its laurels.

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has ...

The FDA and Stealth look set to relitigate the debate, with the biotech planning to file for approval once again. Stealth has ...

Siemens Healthineers has deployed its first mobile stroke unit in the U.S., with an ambulance equipped with its own CT ...

Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move ...

Instead, Stealth submitted a new drug application seeking approval of elamipretide, and the FDA issued its refusal-to-file ...

But on Wednesday, May 28 Moderna revealed the HHS has terminated the award for late-stage development and right to purchase ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

In an effort to maximize the earnings potential of its plaque psoriasis cream, Danish dermatology biotech MC2 Therapeutics ...